Printer Friendly

Research and Markets: Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H2 2012.

DUBLIN -- Research and Markets (http://www.researchandmarkets.com/research/24x56x/plaque_psoriasis) has announced the addition of Global Markets Direct's new report "Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H2 2012" to their offering.

Global Markets Direct's, 'Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H2 2012', provides an overview of the Plaque Psoriasis (Psoriasis Vulgaris) therapeutic pipeline. This report provides information on the therapeutic development for Plaque Psoriasis (Psoriasis Vulgaris), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Plaque Psoriasis (Psoriasis Vulgaris).

Scope

- A snapshot of the global therapeutic scenario for Plaque Psoriasis (Psoriasis Vulgaris).

- A review of the Plaque Psoriasis (Psoriasis Vulgaris) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.

- Coverage of products based on various stages of development ranging from discovery till registration stages.

- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.

- Coverage of the Plaque Psoriasis (Psoriasis Vulgaris) pipeline on the basis of route of administration and molecule type.

- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.

- Key discontinued pipeline projects.

- News and deals relating to the products.

Reasons to Buy

- Identify and understand important and diverse types of therapeutics under development for Plaque Psoriasis (Psoriasis Vulgaris).

- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.

- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.

- Devise corrective measures for pipeline projects by understanding Plaque Psoriasis (Psoriasis Vulgaris) pipeline depth and focus of Plaque Psoriasis (Psoriasis Vulgaris) therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

For more information visit http://www.researchandmarkets.com/research/24x56x/plaque_psoriasis

Source: Global Markets Direct
COPYRIGHT 2013 Business Wire, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2013 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Mar 1, 2013
Words:408
Previous Article:Research and Markets: Autoinjectors to 2018 Devices, Therapeutics, Markets, Strategies and Prospect.
Next Article:Research and Markets: Construction Stone Market in Australia: Business Report 2012.
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters